Pharma News

Lupin Limited has reached a settlement and licensing agreement with Astellas Pharma and its group companies, bringing an end to the long-running patent infringement litigation related to the overactive bladder drug Mirabegron (marketed by Astellas as Myrbetriq).

Lupin said the agreement was signed by the company and its wholly owned US subsidiary, Lupin Pharmaceuticals, Inc., with Astellas Pharma, Inc., Astellas Ireland Co., Ltd., and Astellas Pharma Global Development, Inc.

Researchers have developed an innovative oxygen-boosted microneedle patch that significantly improves drug delivery and photodynamic therapy (PDT) for psoriasis, a chronic inflammatory skin disease that affects millions worldwide.

The study, published in Acta Pharmaceutica Sinica B, describes a dual-section microneedle (MN) patch designed to overcome two major challenges in psoriasis treatment: poor drug penetration through thickened skin and reduced efficacy of PDT caused by low oxygen levels in inflamed lesions.

Advances in soft and sustainable wearable bioelectronics are set to transform personal health monitoring and digital healthcare, according to a new Perspective article published in BIO Integration. Researchers highlight how skin-like wearable systems can continuously track health signals during daily life, moving care beyond occasional hospital visits.

Zydus Lifesciences has achieved a significant regulatory milestone as the U.S. Food and Drug Administration (USFDA) granted Orphan Drug Designation (ODD) to its novel molecule Desidustat for the treatment of Sickle Cell Disease (SCD). The designation highlights the growing recognition of the urgent need for new and effective therapies in this rare and challenging condition.

Low back pain (LBP) is one of the most common health problems worldwide, affecting people of all ages and placing a heavy burden on healthcare systems. Many patients experience persistent discomfort that interferes with work, sleep, and daily activities. Yet in most cases, doctors cannot identify a clear structural cause, making long-term treatment difficult.